Actualités et Activités de Xenon
Dirigeants
Voir l'organigramme avec ses 18 principaux dirigeants
Biographies les plus recherchées chez Xenon
- Ian Mortimer, President, Chief Executive Officer and Director
- Justin Gover, Director
- Steven Gannon, Director
Changements de dirigeants chez Xenon
- Chris Von Seggern, Chief Commercial officer, a quitté l'entreprise (publié le 20 janvier 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez Xenon.
Pharmacie
Xenon a 1 837 concurrents dont Pfizer (Etats—Unis), Johnson & Johnson (Etats—Unis) et Sanofi (France).
Actualités en fusion/acquisition en Pharmacie.
- Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics (publié le 16 juin 2025).
- Juvenescence vient d'annoncer une levée de fonds de 76 millions de dollars. (publié le 22 mai 2025).
- Kincell Bio vient d'annoncer une levée de fonds de 22 millions de dollars. (publié le 22 mai 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Xenon
- Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference | Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update | Xenon Pharmaceuticals Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Xenon
- Xenon sur Wikipédia, Google News & Yahoo Finance en 1-click
- Xenon sur LinkedIn, Twitter & YouTube en 1-click
